ArticleFrontiers in pharmacology2026
Tiantian capsule alleviates low-fiber diet-induced constipation with improved 5-HT-associated gastrointestinal motility and gut microbiota remodeling.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insufficient dietary fiber intake is closely associated with functional constipation. Although laxatives are widely used, their long-term or inappropriate use may cause adverse effects such as diarrhea and electrolyte imbalance. Tiantian Capsule (TTC) is a marketed health food product with reported laxative effects. However, its effects on low-fiber diet (LFD)-induced constipation and the associated biological changes remain incompletely understood. Purpose: This study aimed to evaluate the effects of TTC on LFD-induced constipation and to investigate its experimentally supported mechanisms. Methods: An LFD-induced constipation rat model was established and evaluated using fecal parameters, gastrointestinal (GI) transit assessment, and intestinal histological staining. Colonic transcriptomic profiling was performed to identify potential biological processes associated with TTC intervention. Fecal microbiota profiling and enzyme-linked immunosorbent assay (ELISA) were further used to assess microbiota changes and motility-related GI hormones/neurotransmitters. Results: TTC improved defecation function and restored intestinal histopathological changes in LFD-induced constipation. Colonic transcriptomic analysis suggested that TTC intervention was associated with changes in serotonergic signaling and intestinal immune-related pathways. Consistently, TTC improved GI transit, modulated serum 5-HT and other GI hormones/neurotransmitters levels, and restored fecal microbiota diversity and composition. Conclusion: This study suggests that TTC improves LFD-induced constipation-like phenotypes, accompanied by changes in 5-HT-associated GI motility regulation and fecal microbiota composition, warranting further exploration and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.